Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.21M | $9.87M | $13.1M | $9.88M | $14.5M | $79.0M | $123M | $35.0M | $6.77M | $4.34M |
| Revenue growth | — | 134.6% | 33.0% | -24.8% | 47.0% | 444.6% | 55.2% | -71.5% | -80.6% | -35.8% |
| Gross profit | $997K | $1.95M | $4.78M | $2.62M | $4.61M | $42.0M | $70.7M | $15.6M | -$150K | $1.38M |
| Gross margin | 23.7% | 19.7% | 36.4% | 26.5% | 31.7% | 53.1% | 57.6% | 44.5% | -2.2% | 31.9% |
| Operating income | -$2.66M | -$3.99M | -$1.63M | -$3.24M | -$2.08M | $9.80M | $23.6M | -$21.2M | -$38.6M | -$18.0M |
| Operating margin | -63.1% | -40.4% | -12.4% | -32.8% | -14.3% | 12.4% | 19.2% | -60.7% | -570.6% | -415.4% |
| Net income | -$2.87M | $40.6M | -$1.74M | -$3.15M | -$2.13M | $6.27M | $18.5M | -$16.8M | -$53.4M | -$14.7M |
| Net margin | -68.2% | 411.4% | -13.3% | -31.9% | -14.6% | 7.9% | 15.1% | -48.0% | -788.2% | -339.3% |
| EPS (diluted) | -$0.17 | $2.59 | -$0.15 | -$0.27 | -$0.18 | $0.40 | $1.02 | -$0.98 | -$26.68 | -$1.74 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$472K | -$2.84M | -$2.12M | -$841K | -$2.59M | -$13.6M | $28.6M | -$11.9M | -$17.5M | -$8.34M |
| Capital expenditures | $651K | $208K | $140K | $228K | $1.69M | $4.23M | $3.92M | $2.08M | $906K | $0.00 |
| Free cash flow | -$1.12M | -$3.05M | -$2.26M | -$1.07M | -$4.28M | -$17.9M | $24.6M | -$14.0M | -$18.4M | -$8.34M |
| Share buybacks | — | $16.3M | — | — | — | $917K | $2.15M | $588K | $0.00 | — |
| Dividends paid | — | — | $11.7M | $5.82M | — | $4.55M | $9.35M | $0.00 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $441K | $3.17M | $1.55M | $434K | $6.82M | $8.41M | $9.11M | $1.61M | $678K | $90.0K |
| Total assets | $12.8M | $33.7M | $20.7M | $12.3M | $31.4M | $89.3M | $87.6M | $91.9M | $63.2M | $59.9M |
| Total liabilities | — | — | $4.23M | $1.04M | $20.8M | $30.7M | $24.0M | $42.5M | $55.8M | $56.4M |
| Long-term debt | — | — | — | — | — | — | $0.00 | $2.92M | — | — |
| Shareholders' equity | $5.96M | $31.8M | $16.5M | $11.2M | $10.6M | $58.6M | $63.6M | $49.4M | $7.35M | $3.51M |
| Retained earnings | -$19.7M | $20.9M | $4.53M | -$1.51M | -$3.63M | $2.64M | $11.8M | -$5.03M | -$58.4M | -$73.1M |
| Shares (wtd avg diluted) | 17.1B | 15.7M | 11.4M | — | 11.6M | 18.4M | 18.7M | 17.2M | 2.00M | 8.49M |
Every figure is extracted from ProPhase Labs, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.